当前位置: 首页 >> 检索结果
5413. Socioeconomic Differences in the Epidemiologic Transition From Heart Disease to Cancer as the Leading Cause of Death in the United States, 2003 to 2015: An Observational Study.
作者: Katherine G Hastings.;Derek B Boothroyd.;Kristopher Kapphahn.;Jiaqi Hu.;David H Rehkopf.;Mark R Cullen.;Latha Palaniappan.
来源: Ann Intern Med. 2018年169卷12期836-844页
Recent data suggest that the United States is in the midst of an epidemiologic transition in the leading cause of death.
5414. Premature Mortality From Drug Overdoses: A Comparative Analysis of 13 Organisation for Economic Co-operation and Development Member Countries With High-Quality Death Certificate Data, 2001 to 2015.
作者: Yingxi Chen.;Meredith S Shiels.;David Thomas.;Neal D Freedman.;Amy Berrington de González.
来源: Ann Intern Med. 2019年170卷5期352-354页 5416. Increasing Safe Outpatient Management of Emergency Department Patients With Pulmonary Embolism: A Controlled Pragmatic Trial.
作者: David R Vinson.;Dustin G Mark.;Uli K Chettipally.;Jie Huang.;Adina S Rauchwerger.;Mary E Reed.;James S Lin.;Mamata V Kene.;David H Wang.;Dana R Sax.;Tamara S Pleshakov.;Ian D McLachlan.;Cyrus K Yamin.;Andrew R Elms.;Hilary R Iskin.;Ridhima Vemula.;Donald M Yealy.;Dustin W Ballard.; .
来源: Ann Intern Med. 2018年169卷12期855-865页
Many low-risk patients with acute pulmonary embolism (PE) in the emergency department (ED) are eligible for outpatient care but are hospitalized nonetheless. One impediment to home discharge is the difficulty of identifying which patients can safely forgo hospitalization.
5419. Nonalcoholic Fatty Liver Disease.
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease. Most cases are diagnosed incidentally in the primary care or hospital setting on the basis of elevated liver enzyme levels or hepatic steatosis on imaging. NAFLD encompasses a wide spectrum: The vast majority of patients have nonprogressive nonalcoholic fatty liver, and a few of those develop progressive liver injury, inflammation, and fibrosis, a condition termed nonalcoholic steatohepatitis. Cardiovascular disease is the leading cause of death in patients with nonalcoholic fatty liver disease. Persons with nonalcoholic steatohepatitis have increased liver-related mortality. In the absence of regulatory agency-approved drugs, lifestyle modification and weight loss remain the cornerstones of NAFLD therapy.
|